Search results
Pharma Stock Roundup: LLY's CFO Departs, ABBV, AZN Drugs Get CHMP Approval
Zacks via Yahoo Finance· 2 hours agoLilly launched its successful tirzepatide medicines, diabetes drug Mounjaro and weight loss...
A second animal tranquilizer has infiltrated the state's street drugs, making deadly mark
Detroit Free Press· 19 hours agoLike xylazine before it, the new drug, medetomidine, is a non-opioid animal tranquilizer that is not...
Immunotherapy drug may help 'cure' advanced colorectal cancer without surgery
MedicalNewsToday via AOL· 1 day agoGiving the immunotherapy drug pembrolizumab before surgery instead of chemotherapy may help improve...
Weight-loss injections could halve risk of cancer
The Telegraph via Yahoo News· 3 days agoRong Xu, professor of biomedical informatics and director of CWRU’s centre for artificial intelligence in drug discovery said it was an observational...
Biotech Stock Roundup: GSK's Litigation Update, BIIB's Drug Approval & Other Updates
Zacks via Yahoo Finance· 23 hours agoAll key secondary endpoints (annualized flare rate; flare-free, treatment-free complete remission;...
AbbVie treats first subject in Phase III multiple myeloma drug trial
Clinical Trials Arena via Yahoo Finance· 1 day agoOverall survival, complete response or better, very good partial response or better, the rate of...
AbbVie (ABBV) Starts Late-Stage Study on Multiple Myeloma Drug
Zacks via Yahoo Finance· 1 day agoThe late-stage study will evaluate AbbVie's (ABBV) experimental antibody to treat patients with ...
Sunvozertinib's Global Pivotal WU-KONG1B Study Meets Primary Endpoint in Non-Small Cell Lung Cancer...
The Woonsocket Call· 5 days agoThe global pivotal WU-KONG1B study investigating sunvozertinib achieved its primary objective with a manageable safety profile in relapsed or refractory NSCLC with EGFR exon20ins ...
Blenrep-Based Regimen Yields PFS Benefit in Relapsed/Refractory Myeloma
MedPage Today· 5 days agoAt a median follow-up of 21.8 months, the 12-month estimated PFS rates were 71% with BPd versus 51%...
AbbVie makes oncology progress with two drug trials
Crain s Chicago Business· 22 hours agoMultiple myeloma, the second-most common blood cancer, is characterized by abnormal proliferation of plasma cells, which can cause end-organ damage, AbbVie said in a statement. The start of ...
